OCTAGAM normal immunoglobulin (human) 1g/20mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

octagam normal immunoglobulin (human) 1g/20ml injection vial

octapharma australia pty ltd - human immunoglobulin g, quantity: 50 mg/ml - injection - excipient ingredients: human immunoglobulin a; octoxinol 10; tributyl phosphate; maltose; water for injections - replacement therapy: primary immunodeficiency syndromes: congenital agammaglobulinaemia and hypogammaglobulinaemia; common variable immunodeficiency; severe combined immunodeficiencies; wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. children with congenital acquired immune deficiency syndrome (aids) who have repeated bacterial infections; immunomodulatory effect: idiopathic thrombocytopenic purpura, in adults or children with a high risk of bleeding or prior to surgery to correct platelet count. guillain barre syndrome. kawasaki disease. allogeneic bone marrow transplantation.

CSL ZOSTER IMMUNOGLOBULIN VF (human) 200IU injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

csl zoster immunoglobulin vf (human) 200iu injection vial

csl behring australia pty ltd - human immunoglobulin g, quantity: 160 mg/ml; zoster immunoglobulin, quantity: 200 iu - injection, solution - excipient ingredients: water for injections; glycine; human immunoglobulin a - indications as at 8 august 2002 : zoster immunoglobulin is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma); b. congenital or acquired immunodeficiency; c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact; b. playmate contact (>1 hour play indoors); c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward); d. newborn contact (newborn of mother who had onset of chickenpox <5 days before delivery or within 48 hours after delivery); e. premature infant (>= 28 weeks gestation) whose mother lacks a prior history of chickenpox; f. premature infant (< 28 weeks gestation or <= 1000g) regardless of maternal history. 3. negative or unknown history of chickenpox. 4. if zoster immunoglobulin can be administered within 96 hours after exposure. zoster immunoglobulin, normal immunoglobulin (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.

LG-octaplas, solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

lg-octaplas, solution for infusion

octapharma (ip) sprl - human plasma protein - solution for infusion - . percent volume/volume - blood substitutes and plasma protein fractions

Rivastigmine Sandoz Transdermal Patch 13.3mg/24hours Malta - English - Medicines Authority

rivastigmine sandoz transdermal patch 13.3mg/24hours

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - rivastigmine - transdermal patch - rivastigmine 13.3 mg/24 h - psychoanaleptics

LG-octaplas, Powder and solvent for solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

lg-octaplas, powder and solvent for solution for infusion

octapharma (ip) sprl - human plasma protein - powder and solvent for solution for infusion - blood substitutes and plasma protein fractions

RATIO-RIVASTIGMINE CAPSULE Canada - English - Health Canada

ratio-rivastigmine capsule

teva canada limited - rivastigmine (rivastigmine hydrogen tartrate) - capsule - 1.5mg - rivastigmine (rivastigmine hydrogen tartrate) 1.5mg - parasympathomemetic (cholinergic) agents

RATIO-RIVASTIGMINE CAPSULE Canada - English - Health Canada

ratio-rivastigmine capsule

teva canada limited - rivastigmine (rivastigmine hydrogen tartrate) - capsule - 3mg - rivastigmine (rivastigmine hydrogen tartrate) 3mg - parasympathomemetic (cholinergic) agents

RATIO-RIVASTIGMINE CAPSULE Canada - English - Health Canada

ratio-rivastigmine capsule

teva canada limited - rivastigmine (rivastigmine hydrogen tartrate) - capsule - 4.5mg - rivastigmine (rivastigmine hydrogen tartrate) 4.5mg - parasympathomemetic (cholinergic) agents

RATIO-RIVASTIGMINE CAPSULE Canada - English - Health Canada

ratio-rivastigmine capsule

teva canada limited - rivastigmine (rivastigmine hydrogen tartrate) - capsule - 6mg - rivastigmine (rivastigmine hydrogen tartrate) 6mg - parasympathomemetic (cholinergic) agents

MED-RIVASTIGMINE CAPSULE Canada - English - Health Canada

med-rivastigmine capsule

generic medical partners inc - rivastigmine (rivastigmine hydrogen tartrate) - capsule - 1.5mg - rivastigmine (rivastigmine hydrogen tartrate) 1.5mg - parasympathomemetic (cholinergic) agents